期刊
CANCER
卷 115, 期 9, 页码 1859-1866出版社
WILEY
DOI: 10.1002/cncr.24211
关键词
renal cell carcinoma; immunotherapy; survival; metastases; response criteria; sorafenib; bevacizumab; erlotinib; interferon
类别
资金
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
- NCRR NIH HHS [KL2 RR024149] Funding Source: Medline
BACKGROUND: The standard of care for patients with advanced renal cell carcinoma (RCC) has changed to favor targeted therapy over immunotherapy. Differences in patterns of progression between patients treated with these 2 modalities, and the impact of disease stabilization on outcome, were investigated. METHODS: Patients who progressed on first line antivascular therapy (AVT) or interferon were identified, and their medical records reviewed. RESULTS: A total of 162 patients met inclusion criteria for this analysis. Patients in the AVT group had better baseline performance status, fewer liver metastases, and more responses (CR + PR) compared with the interferon group. Both groups were equally likely to develop distant metastases; however, for patients in the AVT group, these new metastases were more likely to arise in the setting of controlled disease at baseline sites (18% vs 4%, P = .012). There was no difference in anatomic sites of progression between the 2 groups. Patients responding (CR + PR) to AVT trended toward longer progression-free survival (PFS) compared with patients with stable disease (SD) (P = .06). No difference between responders and SD was seen in the interferon group. CONCLUSIONS: Patients with RCC treated with antivascular therapy were more likely to progress at new sites in the setting of stable disease at baseline sites, suggesting that AVT may be more effective at controlling existing sites of disease than it is at preventing new metastases. Patients with SD on AVT had shorter PFS compared with responders (CR + PR). Whether this relationship extends to overall survival requires further study. Cancer 2009;115:1859-66. (C) 2009 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据